DEFA14A ·Filed Apr 28, 2026

CABA

Cabaletta Bio, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed5mo ago SEC0001193125-26-183564
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for any activist campaigns or further filing details regarding the share increase. The doubling of authorized shares could lead to dilution if issued.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CABA ▼ -4.90% at T+60d
NEUTRAL call ✗ call lost -4.90% · α vs SPY -8.88% · entry $2.86 → $2.72
Entry anchored
Apr 28, 2026
via day open
T+1d
-2.80%
call -2.80% · α -2.79%
$2.78
settled 5mo ago
T+5d
+45.10%
call +45.10% · α +43.41%
$4.15
settled 5mo ago
T+20d
+33.92%
call +33.92% · α +28.46%
$3.83
settled 4mo ago
T+60d
-4.90%
call -4.90% · α -8.88%
$2.72
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Cabaletta Bio files additional proxy materials for its 2026 annual meeting. The board recommends voting FOR all proposals including election of two Class I directors, ratification of Ernst & Young as auditor, approval of amendments to the 2019 stock plan and charter to double authorized shares, say-on-pay, and adjournment. The most notable item is the proposed increase in authorized common stock from 300M to 600M, signaling potential future dilution.

Key Facts

  • Annual meeting scheduled for June 9, 2026
  • Stockholders of record as of April 20, 2026
  • Proposal to double authorized shares from 300M to 600M
  • Amendment to 2019 Stock Option and Incentive Plan
  • Board unanimously recommends FOR all six proposals

Financial Impact

Not specified

Risk Factors

  • Potential shareholder dilution if authorized shares are issued
  • No material financial data disclosed in this filing

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-183564
Document: 0001193125-26-183564-index-headers.html0001193125-26-183564
Document: 0001193125-26-183564-index.html0001193125-26-183564
Document: 0001193125-26-183564.txt0001193125-26-183564
17 reports for CABA
Performance horizon
75% Hit rate 6 of 8 directional calls best @ T+60▲ +31.59%May 4, 2026
Filters
Rows
Reports for CABA — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
8-K
NEUTRAL ★ 4/10
$2.91 $2.46▼ −15.46%▼ −15.57%$1.91 (−34.36%)
Aug 15, 2026
6w ago
Institutional Cluster
BULLISH ★ 5/10
$2.89 $3.10▲ +7.27%▲ +8.46%$1.91 (−33.91%)
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$2.71 $3.19▲ +17.71%▲ +19.68%$1.91 (−29.52%)
Aug 13, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$2.71 $3.19▲ +17.71%▲ +19.68%$1.91 (−29.52%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 5/10
$3.01 $2.84▼ −5.65%▼ −6.32%$1.91 (−36.54%)
Jun 3, 2026
17w ago
8-K
BULLISH ★ 7/10
$3.58 $3.04▼ −15.08%▼ −11.26%$1.91 (−46.65%)
Jun 1, 2026
17w ago
DEFA14A
NEUTRAL ★ 3/10
$3.67 $3.25▼ −11.44%▼ −8.69%$1.91 (−47.96%)
May 14, 2026
20w ago
8-K
BEARISH ★ 6/10
$3.61 $3.69▼ −2.22%▼ −2.93%$1.91 (+47.09%)
May 14, 2026
20w ago
Press Release
NEUTRAL ★ 4/10
$3.61 $3.69▲ +2.22%▲ +2.93%$1.91 (−47.09%)
May 14, 2026
20w ago
8-K
BULLISH ★ 7/10
$3.61 $3.69▲ +2.22%▲ +2.93%$1.91 (−47.09%)
Showing 10 of 17

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access